Yahoo Finance

Operations: Informa generates revenue through its four primary segments: Informa Tech (£426.70 million), Informa Connect (£630.20 million), Informa Markets (£1.67 billion), and Taylor & Francis (£636.70 million).

Informa has demonstrated resilience with a forecasted revenue growth of 7.7% per year, outpacing the UK market's average of 3.5%, despite a challenging backdrop marked by a significant one-off loss of £213.5 million affecting its financial results up to June 30, 2024. The company's strategic initiatives, including recent fixed-income offerings totaling over €1.74 billion and active participation in global conferences, underscore its commitment to strengthening its market position and expanding its international footprint. Moreover, earnings are expected to surge by an impressive 22.4% annually, highlighting Informa's potential for robust financial performance amidst evolving industry dynamics.

• Get an in-depth perspective on Informa's performance by reading our health report here.

• Explore historical data to track Informa's performance over time in our Past section.

Oxford Biomedica

Simply Wall St Growth Rating: ★★★★★☆

Overview: Oxford Biomedica plc is a contract development and manufacturing organization specializing in delivering therapies globally, with a market capitalization of £447.25 million.

Operations: Oxford Biomedica generates revenue primarily from its Platform segment, amounting to £97.24 million. The company operates as a contract development and manufacturing organization, focusing on global therapeutic delivery.

Oxford Biomedica, amid a challenging biotech landscape, stands out with its aggressive growth trajectory, forecasting a revenue increase of 21% per year. This rate significantly surpasses the UK's average market growth of 3.5%. The company is also poised for substantial earnings expansion, with an expected surge of 93.2% annually. These figures underscore Oxford Biomedica’s commitment to innovation and market expansion, particularly highlighted by their recent strategic executive appointments and robust R&D investments which align with their forward-looking financial guidance projecting revenues between £126 million and £134 million by the end of 2024.

• Take a closer look at Oxford Biomedica's potential here in our health report.

• Assess Oxford Biomedica's past performance with our detailed historical performance reports.

Next Steps

• Gain an insight into the universe of 47 UK High Growth Tech and AI Stocks by clicking here.

• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.

• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AIM:GBG LSE:INF and LSE:OXB.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com